Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo‐controlled, double‐blind, parallel‐group study
- 21 November 2016
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 19 (6) , 773-782
Abstract
Aim: Glucagon‐like peptide‐1 receptor agonist ( GLP‐1RA ) therapy is a potential treatment as adjunct to insulin in type 1 diabetes ( T1D ). However, GLP‐1RAs inhibit glucagon secretion and delay the gastric emptying ( GE ) rate and may impair recovery from hypoglycaemia. We evaluated the effect of the GLP‐1RA liraglutide on counterregulatory responses and GE rate during hypoglycaemia in persons with T1D . Materials and methods: In a 12‐week, randomized, double‐blind, placebo‐controlled study, 20 patients aged >18 years with T1D and HbA1c ≥8% (64 mmol/mol) were randomly assigned (1:1) to liraglutide 1.2 mg once daily or placebo as add‐on to insulin treatment. Before and at end of treatment a hypoglycaemic clamp (plasma glucose target 2.5 mmol/ L ) was carried out, followed by a liquid meal. Primary endpoint was change in GE rate (evaluated by area under the paracetamol curve and time to peak). Secondary endpoints included changes in glycaemic recovery, counter‐regulatory hormones, pancreatic polypeptide ( PP ), GLP ‐1, blood pressure and heart rate. Results: During the period J une 2013 to O ctober 2014, 20 patients were enrolled. After 12 weeks of treatment, changes in GE rates did not differ significantly between groups ( P = .96), with no significant changes from baseline, whether evaluated from AUCs or time to peak. The secondary endpoints, glycaemic recovery, counter‐regulatory hormone responses, systolic blood pressure and GLP ‐1 and PP responses, were also similar. Heart rate increased with liraglutide from 69 ± 4 to 80 ± 5 beats/min ( P = .02). Conclusions: Liraglutide does not compromise glycaemic recovery, GE rate or counter‐regulatory hormone responses in T1D patients during hypoglycaemia. No treatment‐related safety issues were identified.Keywords
Funding Information
- Johnson and Johnson
- Novartis Pharma
- Pfizer
This publication has 33 references indexed in Scilit:
- Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized TrialDiabetes Care, 2016
- Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized TrialDiabetes Care, 2016
- Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 WeeksDiabetes Care, 2016
- Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel StudyDiabetes Care, 2015
- Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell FunctionDiabetes, 2011
- Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patientsDiabetes Care, 1996
- Adverse Events and Their Association With Treatment Regimens in the Diabetes Control and Complications TrialDiabetes Care, 1995
- Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDMDiabetologia, 1995
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes MellitusNew England Journal of Medicine, 1992